Unitaid’s 50th Executive Board meeting Summary
The 50th Executive Board highlighted Unitaid’s strong organisational performance despite a challenging global health financing environment. Discussions focused on sustaining equitable access to health innovations, strengthening domestic financing, preparing the next organisational strategy, and responding to an increasingly constrained funding landscape.
Organisational Performance
Board members commended the Executive Director and Secretariat for delivering strong 2025 results, as outlined in its strategy implementation report. Unitaid-supported products now reach approximately 390 million people annually across more than 100 countries, with continued progress in women’s health, medical oxygen, regional manufacturing and access planning. Board members welcomed improvements in staff satisfaction, grant development timelines and the growing influence of Unitaid-supported products in WHO guidance and global procurement.
Strategy Implementation & Portfolio
The Board welcomed strong delivery across all strategic objectives but recognised that scale-up remains constrained by shrinking global health financing rather than portfolio performance. Discussions focused on embedding access planning earlier, strengthening market shaping, reducing intellectual property barriers, supporting regional manufacturing and improving pathways from innovation to country adoption. NGOs stressed the need for greater transparency around scalability risks and continued focus on affordability and equitable access.
Operating Model & Next Strategy
The Board approved a new ‘Reinforcements Pathway’ to allow timely investment in strategic opportunities linked to existing grants. Board members requested clear eligibility criteria and safeguards to maintain implementer diversity and country ownership. The Board also approved the process for developing Unitaid’s next strategy, emphasising meaningful engagement with countries, civil society and communities, consideration of different funding scenarios, and careful reflection on Unitaid’s future role within the evolving global health architecture.
Resource Mobilisation
Unitaid has raised US$696 million towards its US$1.5 billion funding target for the 2023-2027 Strategy. This year, it is forecast to raise just US$140 million, less than half of its annual target of US$300 million. The difficult funding environment was raised in many Board discussions. Official development assistance is falling significantly, creating a substantial gap between available resources and Unitaid’s ambitions. Whilst Board members welcomed the update on Unitaid’s progress on philanthropic partnerships, catalytic finance and results-based financing, they stressed that core funding remains essential. NGOs called for greater transparency on fundraising progress, clearer reporting on financing mechanisms and continued safeguards to protect affordability, equity and country ownership.
Investment Plan & New Areas for Intervention (AfIs)
The Board discussed future Areas for Intervention on newborn care and integrated TB/hepatitis C services for vulnerable populations. Board members broadly supported both priorities whilst emphasising strategic country engagement, partnerships, sustainability planning and meaningful civil society participation. NGOs also highlighted the need to maintain attention on HIV, women’s health, cervical cancer, point-of-care diagnostics and intellectual property investments as resources become increasingly constrained. NGOs supported both AfIs and, for the TB/HCV AfI, recommended specifying target countries once finalised and requested Unitaid invest in engagement for a second tier of countries beyond implementing countries as part of an event to replicate best practices.
Financial Oversight & Governance
The Board approved the audited financial statements, noting strong financial management and budget execution while encouraging improvements in transparency, grant closure processes and reporting. Governance arrangements, including the committee leadership of both the Policy and Strategy Committee (PSC), the Finance and Accountability Committee (FAC) and the Governance Working Group (GWG), as well as the Vice-Chair appointment, were extended for one year.
Key Board Decisions
- Approved the ‘Reinforcements Pathway’ optimisation to the operating model.
- Approved the process for developing Unitaid’s next strategy by June 2027.
- Approved the two new areas for intervention.
- Approved the audited financial statements.
- Extended Board governance arrangements for the PSC, FAC, GWG and Vice-Chair until 202
Recent Comments